Abstract
The pharmaceutical industry is exhaustively exploring novel targets in the
search for new drugs to treat inflammatory diseases. Delving in-depth into
these efforts, this report provides:
- An analysis of six diseases: rheumatoid arthritis, inflammatory bowel
disease, psoriasis, lupus, multiple sclerosis, and asthma
- An assessment of existing drug therapies for these diseases
- Discussion of pharmacological R&D strategies being employed by the
industry in developing both biological and small-molecule agents for these
diseases
- Review of the approximately 200 compounds in clinical development and
assessment of particularly noteworthy drug candidates for these diseases
- Autoimmune disorders and asthma have drawn a great deal of attention from
the pharmaceutical industry. The most successful new approach to treating
inflammatory diseases in the last decade has addressed the pro-inflammatory
role of cytokines, notably TNF-alpha, in these types of conditions. Three
TNF-alpha blockers-Enbrel (etanercept), Remicade (infliximab), and Humira
(adalimumab)-are now marketed for treating a range of autoimmune diseases, and
they enjoy true blockbuster status, with aggregate sales topping $9 billion in
2006.
Nevertheless, the door remains open for improved therapeutics. Some patients
do not respond to the TNF-alpha inhibitors; the effectiveness of the agents
depends on long-term, even lifelong, administration; and they have been linked
to tuberculosis, lymphoma, and other adverse effects.
Several new biological agents have begun to carve their own niches in the
massive edifice of the TNF-alpha blockers. Orencia (abatacept), a T-cell
co-stimulation modulator, was approved for the treatment of rheumatoid
arthritis in 2005; Rituxan (rituximab), an anti-CD20 antibody, for rheumatoid
arthritis in 2006; and Tysabri (natalizumab), an adhesion molecule blocker,
for multiple sclerosis in 2006 and Crohn' s disease in 2008.
A recurrent theme in discussions of treatment options for autoimmune diseases
is the inadequacy of the standard of care. Management and pharmacotherapy are
seeing only incremental improvements. Patients with asthma, an allergic
disease, tend to fare well with the drugs currently available, though better
treatment options with less potential for side effects are needed.
The complexity of the immune system provides both opportunity and challenge
for the pharmaceutical industry. There is a seemingly endless list of
cytokines, receptors, and enzymes that can be disrupted in patients with
autoimmune and inflammatory diseases, and the sheer number of options leaves
plenty of chances for companies-large established players and specialized
newcomers alike-to carve out niches. On the other hand, the transition from
brainstorm to marketed drug is fraught with pitfalls. Targeting a single
receptor or protein often means being foiled by the immune system' s
redundancy, while cutting too wide a swath through the system can result in
unexpected side effects.
Table of Contents
Chapter 1 INTRODUCTION: THE IMMUNE SYSTEM AND THE INFLAMMATORY RESPONSE
- 1.1. The Immune System
- 1.2. Immune Dysfunction and Autoimmune Disease
Chapter 2 REVIEW OF THE INFLAMMATORY DISEASES: EPIDEMIOLOGY, PATHOLOGY, DIAGNOSIS, AND SYMPTOMS
- 2.1. Rheumatoid Arthritis
- Pathology
- Causes
- Diagnosis
- Epidemiology
- 2.2. Inflammatory Bowel Disease
- Pathology
- Causes
- Diagnosis
- Epidemiology
- 2.3. Psoriasis
- Pathology
- Causes
- Diagnosis
- Epidemiology
- 2.4. Lupus
- Pathology
- Causes
- Diagnosis
- Epidemiology
- 2.5. Multiple Sclerosis
- Pathology
- Causes
- Diagnosis
- Epidemiology
- 2.6. Asthma
- Pathology
- Causes
- Diagnosis
- Epidemiology
Chapter 3 CURRENT PHARMACOLOGICAL TREATMENT OPTIONS
- 3.1. Rheumatoid Arthritis
- Analgesics and NSAIDS
- Corticosteroids
- Synthetic DMARDs
- Methotrexate
- Arava (Leflunomide)
- Other DMARDs
- Biological DMARDs
- Enbrel (Etanercept)
- Remicade (Infliximab)
- Humira (Adalimumab)
- Kineret (Anakinra)
- Orencia (Abatacept)
- Rituxan (Rituximab)
- 3.2. Inflammatory Bowel Disease
- Aminosalicylates
- Corticosteroids
- Immunomodulators
- Azathioprine, 6-Mercaptopurine, and 6-Thioguanine
- Methotrexate
- Cyclosporine
- Remicade (Infliximab)
- Humira (Adalimumab)
- Tysabri (Natalizumab)
- Antibiotics
- 3.3. Psoriasis
- Topical Therapies
- Corticosteroids
- Vitamin D3 and A Compounds
- Retinoids
- Coal Tar
- Anthralin
- Salicylic Acid
- Light Therapy
- Systemic Therapy
- Methotrexate
- Cyclosporine
- Oral Retinoids
- Hydroxyurea
- Amevive (Alefacept)
- Raptiva (Efalizumab)
- Enbrel (Etanercept)
- Remicade (Infliximab)
- Humira (Adalimumab)
- 3.4. Lupus
- NSAIDs
- Antimalarials
- Corticosteroids
- Immunomodulators
- 3.5. Multiple Sclerosis
- Corticosteroids
- Disease-Modifying Agents
- Interferon Beta
- Copaxone (Glatiramer Acetate)
- Novantrone (Mitoxantrone)
- Tysabri (Natalizumab)
- Other Immunomodulators
- 3.6. Asthma
- Quick-Relief Medications
- Bronchodilators
- Oral Corticosteroids
- Long-Term Control Medications
- Inhaled Corticosteroids
- Bronchodilators
- Mast Cell Stabilizers
- Leukotriene Modifiers
- Xolair (Omalizumab)
Chapter 4 COMPOUNDS IN DEVELOPMENT: THE NEXT GENERATION OF DRUGS FOR INFLAMMATORY DISEASES
- 4.1. New Approaches to Inflammatory Diseases
- Tumor Necrosis Factor Family Inhibitors
- Interleukin Inhibitors
- Other Cytokine Inhibitors
- Chemokine Receptor Antagonists
- Anti-inflammatory Cytokines
- Compounds Targeting T-Cell Antigens
- Compounds Targeting B-Cell Antigens
- Complement Inhibitors
- Adhesion Molecule Blockers
- Protease Inhibitors
- Kinase Inhibitors
- Other Kinases
- 4.2. Setbacks
- 4.3. Rheumatoid Arthritis
- TNF-alpha Inhibitors
- UCB
- Centocor
- Targeted Genetics
- Arana Therapeutics
- Xencor
- Meyer Pharmaceuticals
- Pharmaxis
- Ception Therapeutics
- Ablynx
- Nastech Pharmaceutical
- Devgen
- Interleukin Inhibitors
- Kinase Inhibitors
- Rigel Pharmaceuticals
- Plexxikon
- 4.4. Inflammatory Bowel Disease
- Adhesion Molecule Blockers
- Atlantic Healthcare
- Millennium Pharmaceuticals
- Other Compounds
- InDex Pharmaceuticals
- Genzyme
- 4.5. Psoriasis
- TNF Inhibitors
- Apollo Life Sciences
- York Pharma
- Interleukin Inhibitors
- Centocor
- Abbott Laboratories
- Calcineurin Inhibitors
- Isotechnika
- Biogen Idec
- CombinatoRx
- Celgene
- Vitamin D Analogs
- CollaGenex Pharmaceuticals
- Cytochroma
- 4.6. Lupus
- Immunomodulators
- La Jolla Pharmaceutical
- Genelabs Technologies
- BLyS Inhibitors
- Human Genome Sciences
- ZymoGenetics
- Anthera Pharmaceuticals
- Biogen Idec/Genentech
- Xencor
- Toll-like Receptor Antagonists
- Coley Pharmaceutical Group
- Dynavax Technologies
- Idera Pharmaceuticals
- 4.7. Multiple Sclerosis
- Immunomodulators
- Biogen Idec
- Genzyme/Bayer Schering Pharma
- Novartis
- Cytokines
- Nastech Pharmaceutical
- Syntonix Pharmaceuticals
- Ichor Medical Systems
- Nautilus Biotech
- Flamel Technologies
- Modigene
- Bolder BioTechnology
- CoGenesys
- Allozyne
- Peptide Vaccines and MBP-Base Therapeutics
- Orchestra Therapeutics
- BioMS Medical/Eli Lilly
- Bayhill Therapeutics
- Remyelinating Agents
- Biogen Idec
- Acorda Therapeutics
- 4.8. Asthma
- Interleukin Inhibitors
- GlaxoSmithKline
- MedImmune/BioWa
- Aerovance
- Amgen
- Genentech
- Altair Therapeutics
- CSL/Merck
- Synairgen
- Phosphodiesterase-4 Inhibitors
- Nycomed
- Glenmark Pharmaceuticals/Forest Laboratories
- MediciNova
- Other PDE4 Inhibitors
- Toll-like Receptor Agonists
- Coley Pharmaceutical Group/Sanofi-Aventis
- Dynavax Technologies
- Idera Pharmaceuticals
- InDex Pharmaceuticals
- CRTH2 Antagonists
References
Company Index with Web Addresses
医薬品
その他のカテゴリ
FAQ